
Food safety, germs, fatigue, taste changes and tough questions can make Thanksgiving harder during cancer treatment. Here are five ways to plan ahead.

Spencer, Senior Content Associate of CURE®, has been with MJH Life Sciences since 2024. A graduate of Rowan University with a bachelor's degree in health communication, Spencer manages CURE's content strategy across all platforms. He also enjoys spending time with family and friends, hiking, playing guitar and rock climbing.

Food safety, germs, fatigue, taste changes and tough questions can make Thanksgiving harder during cancer treatment. Here are five ways to plan ahead.

Adding Anktiva to BCG led to better responses than BCG alone in people with high-risk bladder cancer who had not yet received BCG, the company said.

Dr. Rebecca Dent explains how Datroway kept brain metastases in check longer than chemotherapy in triple-negative breast cancer, and what patients should know.

Dr. Matteo Lambertini explains how Lynkuet reduced hot flashes in people on endocrine therapy for breast cancer, no matter when their treatment began.

The FDA granted accelerated approval to Rybrevant Faspro for recurrent or metastatic head and neck cancer that grew after chemotherapy and immunotherapy.

Dr. Sara Hurvitz explains why giving Enhertu before surgery didn't change care for HER2-low, HR-positive early breast cancer, and what patients should know.

Eileen Carter was told she had two to three years to live after a stage 4 breast cancer diagnosis. A second opinion changed her care.

Diagnosed with stage 4 breast cancer weeks after giving birth, Eileen Carter and her chaplain husband share why a second opinion changed everything.

Five colorectal cancer trials recently began treating patients, testing targeted drugs, bispecific antibodies and immunotherapy. Here’s what each one is studying.

A custom mRNA vaccine is the first to succeed in a phase 3 trial. Learn how personalized cancer vaccines work and what to watch for at ESMO 2026.

A rising PSA after surgery or radiation can be frightening. Learn what biochemical recurrence means, which tests come next and your treatment options.

Five CURE bloggers living with breast cancer share what Breast Cancer Awareness Month can miss, from metastatic disease to men and mammogram limits.

From a personalized melanoma vaccine to new options for biliary, stomach, lung and endometrial cancers, here are 5 ESMO 2026 abstracts to watch.

Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.

The FDA has granted two Breakthrough Therapy Designations to AbbVie's investigational drug Temab-A, one for use in metastatic colorectal cancer and one for non-small cell lung cancer, based on early-phase trial data.

Breast cancer survivor Sue Weldon discusses survivorship gaps, integrative therapies alongside treatment and why caregivers should prioritize themselves.

Dr. Nitin Ohri explains how radiation treats cancer, how often treatment is needed, common side effects and how to tell if radiation is working.

Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.

A combination of Zenbexus, Darzalex and dexamethasone nearly doubled the rate of deep, MRD-negative responses in relapsed multiple myeloma.

Dr. Maureen McEvoy explains breast cancer surgery options, reconstruction, recovery and how to close gaps in access to care.

An expert discusses August's FDA approvals for myeloma, polycythemia vera and essential thrombocythemia, plus first-line myeloma care and MRD testing.

A genomic test led physicians to change extended endocrine therapy recommendations for 42% of people with early-stage HR-positive breast cancer.

These seven breast cancer clinical trials are recruiting patients now, spanning early-stage, HR-positive, HER2-positive and triple-negative disease.

In the latest installment of CURE's "Text a Survivor" series, Brad Moore answers some of the most common questions people have about living with and beyond a colorectal cancer diagnosis.

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.

September is Blood Cancer Awareness Month, and the pipeline for leukemia, lymphoma and myeloma is as active as it has been in years.

Dr. Dina Khalaf explains the ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 trials and what patients with AML or MDS should ask before enrolling.

WCLC 2026 brought new lung cancer data on HER2-mutant, PD-L1-positive and EGFR exon 20 insertion-positive non-small cell lung cancer. Here's what patients should know about three key studies.

Hargitay shared her thoughts with CURE regarding her father’s journey, her motivation for speaking out now, and the key message she wants to convey to patients today.

A new study found alcohol-attributable cancer deaths in the U.S. rose from 11,361 in 1990 to 23,126 in 2023, with men and older adults most affected.

Published: August 11th 2026 | Updated: October 29th 2026

Published: August 22nd 2025 | Updated: August 25th 2025

Published: February 5th 2025 | Updated: May 19th 2025

November 19th 2024

January 20th 2026